How to Buy Stoke Therapeutics Stock
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.
Stoke Therapeutics stock last closed at $11.53, down 2.45% from the previous day, and has decreased 34.19% in one year. It has overperformed other stocks in the Biotechnology industry by 0.42 percentage points. Stoke Therapeutics stock is currently +115.51% from its 52-week low of $5.35, and -30.63% from its 52-week high of $16.62.
As of Jun 13, 2025, there are 54.6M STOK shares outstanding. The market cap of STOK is $629.50M. In the last 24 hours, 478,000 STOK shares were traded.
How to Buy Stoke Therapeutics Stock
Not sure how to invest in Stoke Therapeutics stock? Here's how.
- Decide where to buy Stoke Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you figure out where to buy Stoke Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your payment method and add your details.
- Evaluate Stoke Therapeutics stock: The Stoke Therapeutics ticker symbol is STOK. Is Stoke Therapeutics stock a good investment? Should you buy shares of STOK? How do STOK's underlying business fundamentals look? Do top analysts think Stoke Therapeutics is a good buy? Why has STOK's stock price moved recently? (Hint: Our stock market analysis website can help you decide if STOK is a good stock to buy).
- Place your STOK purchase: Decide if you will purchase STOK shares at the current market price or use a limit order to buy STOK stock at a particular price.
- Track your STOK position: Create a watchlist to get the latest news on your investment in Stoke Therapeutics stock.
Step 1: Decide where to buy Stoke Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy STOK shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal info so you can buy STOK stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to open your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on the best stock trading app, you can securely and quickly fund your account:
Check out the walkthrough below if you need help transferring money into your new brokerage account.
Step 4: Evaluate Stoke Therapeutics stock
Once you have chosen the best place to buy Stoke Therapeutics stock, it's important to evaluate their stock before you invest, so you truly comprehend the risk and upside.
Stoke Therapeutics Numbers
Stoke Therapeutics Due Diligence Score
WallStreetZen was built to help everyday investors perform better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on STOK's stock page.
Is STOK stock properly valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge STOK's true value.
Using relative valuations measures:
- STOK could be undervalued based on its P/E ratio of 13.56x, relative to Biotechnology industry P/E ratio of -108.97x
- STOK could be undervalued based on its P/B ratio of 1.8x, relative to Biotechnology industry P/B ratio of 4.66x
You can access more valuation analysis on STOK's stock here.
STOK Financial Health Overview
Pros:
- There are more short-term assets than long-term liabilities on the STOK balance sheet.
- There are more short-term assets than short-term liabilities on the STOK balance sheet.
- STOK has a low debt to equity ratio of 0.16.
- STOK's operating cash flow of $69.54M allows it to safely service it's debt of $0.00.
- STOK earnings of $38.45M is not sufficient to cover its interest payments.
- STOK profit margin has gone up from -1,383.4% to 26.3% in the past year.
Cons:
- Total STOK debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy STOK stock
Out of 3 Equities analysts who give forecasts on STOK, the consensus analyst rating on Stoke Therapeutics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are projecting on the Stoke Therapeutics stock forecast page.
Metrics for Advanced STOK Traders
STOK Performance Metrics
Last year, STOK revenue was $190.91M. Over the last three year, STOK's revenue has gone up by 397.14% per year. This was faster than the Biotechnology industry average of 43.24%.
You can research STOK's earnings and revenue performance here.
Are STOK executives and large shareholders buying or selling the stock?
In the past 12 months, executives and large shareholders at STOK have sold more shares than they have bought.
Trust Skorpios, 10% Owner of STOK, was the latest STOK insider to sell. They sold $30,600,000.00 worth of STOK stock on Jun 4, 2025.
Get more info about who owns STOK shares here.
Can I get consistent income from STOK stock?
No, Stoke Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about STOK
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your STOK purchase
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular price limit, use a limit order.
Hit the Open button and your broker will place your order.
If you need additional help with investing in stocks on eToro, watch the how to video below:
Step 6: Track your STOK position
Now that you own some STOK stock, you'll want to stay up-to-date on your investment.
Start a watchlist to track your STOK stock.
STOK Feed
How to Buy Stock in Stoke Therapeutics
To reiterate, here are the 6 steps you need to take to buy Stoke Therapeutics stock right now:
- Decide where to buy Stoke Therapeutics stock
- Create your brokerage account
- Deposit funds into your investment account
- Evaluate Stoke Therapeutics stock
- Place your STOK purchase
- Track your STOK position
If you need a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Stoke Therapeutics, add STOK to your watchlist by clicking the button below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.